Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review

Eur J Haematol. 2020 Jun;104(6):519-525. doi: 10.1111/ejh.13394. Epub 2020 Feb 27.

Abstract

A common inquiry in coagulation laboratories is how to interpret an unexpected, isolated prolonged activated partial thromboplastin time (APTT). In this context, isolated means together with a normal prothrombin time (PT) and/or normal international normalized ratio (INR). This finding may lead to contact with laboratory doctors for further advice on a diagnostic strategy. Occasionally, the need for a diagnostic algorithm can be subacute, where surgery has to be postponed until an explanation for the isolated, prolonged APTT has been established. Activated partial thromboplastin time as a coagulation test was developed to monitor patients with hemophilia. Different APTT reagents display considerable differences in their sensitivity to deficiencies of coagulation factors. An isolated, prolonged APTT is seen in (a) individuals/patients with lupus anticoagulants, (b) patients in treatment with anticoagulants, mainly heparin, and (c) patients with deficiencies of specific coagulation factors. In this tutorial review, we summarize what may cause an isolated prolonged APTT and we present a simple diagnostic algorithm to differentiate between lupus anticoagulants (common) and factor deficiencies (rare). The identification of an isolated prolonged APTT as well as the underlying cause can be of the utmost importance in ensuring the correct therapeutic follow-up.

Keywords: activated partial thromboplastin time; hemophilia; lupus anticoagulants.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Blood Coagulation Disorders / diagnosis
  • Blood Coagulation Disorders / epidemiology
  • Blood Coagulation Disorders / etiology
  • Blood Coagulation Factors
  • Blood Coagulation*
  • Clinical Decision-Making
  • Diagnosis, Differential
  • Disease Management
  • Disease Susceptibility
  • Drug Interactions
  • Humans
  • Incidental Findings*
  • International Normalized Ratio
  • Lupus Coagulation Inhibitor
  • Partial Thromboplastin Time* / methods
  • Partial Thromboplastin Time* / standards
  • Prevalence

Substances

  • Blood Coagulation Factors
  • Lupus Coagulation Inhibitor